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BACKGROUND Percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG)
are being applied to high-risk populations, but previous randomized trials comparing
revascularization methods have excluded a number of important high-risk groups.
OBJECTIVES This five-year, multicenter, randomized clinical trial was designed to compare long-term
survival among patients with medically refractory myocardial ischemia and a high risk of
adverse outcomes assigned to either a CABG or a PCI strategy, which could include stents.
METHODS Patients from 16 Veterans Affairs Medical Centers were screened to identify myocardial
ischemia refractory to medical management and the presence of one or more risk factors for
adverse outcome with CABG, including prior open-heart surgery, age .70 years, left
ventricular ejection fraction ,0.35, myocardial infarction within seven days or intraaortic
balloon pump required. Clinically eligible patients (n 5 2,431) underwent coronary
angiography; 781 were angiographically acceptable; 454 (58% of eligible) patients consented
to random assignment between CABG and PCI.
RESULTS A total of 232 patients was randomized to CABG and 222 to PCI. The 30-day survivals for
CABG and PCI were 95% and 97%, respectively. Survival rates for CABG and PCI were
90% versus 94% at six months and 79% versus 80% at 36 months (log-rank test, p 5 0.46).
CONCLUSIONS Percutaneous coronary intervention is an alternative to CABG for patients with medically
refractory myocardial ischemia and a high risk of adverse outcomes with CABG. (J Am Coll
Cardiol 2001;38:143–9) © 2001 by the American College of Cardiology
Coronary artery bypass graft (CABG) surgery is associated
with relief of symptoms and enhanced survival relative to
medical therapy in selected patients with coronary artery
disease (CAD) (1–10). Percutaneous coronary intervention
([PCI] can include stents or atherectomy, in addition to
balloon angioplasty) is associated with relief of symptoms
relative to medical therapy in selected patients (11–14).
Direct comparison of PCI versus CABG suggests that long-
term survival is comparable, albeit with more frequent repeat
revascularization, among patients randomized to PCI (15–
24). In some cases, better symptom relief has been observed
among patients randomly assigned to CABG (15–24).
All previous randomized comparisons of PCI with
CABG have excluded patients with prior heart surgery,
on-going or very recent myocardial infarction (MI) and
severe left ventricular dysfunction, defined as left ventricular
From the *Tucson VA Medical Center and the University of Arizona SAVAHCS,
Tucson, Arizona; †Hines CSPCC VA Hospital, Hines, Illinois; ‡Denver VA
Medical Center, Denver, Colorado; §New York VA Medical Center, New York,
New York; \Memphis VA Medical Center, Memphis, Tennessee; ¶Little Rock VA
Medical Center, Little Rock, Arkansas; #Albuquerque VA Medical Center, Albu-
querque, New Mexico; **West Roxbury VA Medical Center, West Roxbury,
Massachusetts; ††Durham VA Medical Center, Durham, North Carolina;
‡‡Asheville VA Medical Center, Asheville, North Carolina; §§Lexington VA
Medical Center, Lexington, Kentucky; and the \ \Kansas City VA Medical Center,
Kansas City, Missouri. Supported by the Cooperative Studies Program of the United
States Department of Veterans Affairs Research and Development Service. This study
was presented in abstract form as a Late Breaking Trial at the Society for Cardiac
Angiography and Interventions meeting, May 2001, Houston, Texas.
Manuscript received December 18, 2000; revised manuscript received March 27,
2001, accepted April 6, 2001.
Journal of the American College of Cardiology Vol. 38, No. 1, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01366-3
ejection fraction (LVEF) ,0.35 (15–24). No previous
revascularization trial has specified medically refractory
ischemia as an inclusion criterion (1–24). The nine reported
randomized comparisons of PCI with CABG did not
include the use of either stents or glycoprotein IIb/IIIa
receptor-blocker drugs, both of which are currently com-
monly used with PCI (15–24).
Although it is difficult to define simple criteria for
medically refractory ischemia that apply to diverse popula-
tions, it is clear that there are patients for whom medical
therapy fails to control their symptoms (25). Similarly, there
are patients with medically refractory ischemia who are turned
down by surgeons for CABG, based on the perception of
prohibitively high operative risk (26). In 1988, we began
offering PCI, without surgical standby, to select patients with
medically refractory ischemia who had been refused CABG
(27). As experience with “salvage angioplasty” increased, the
question was raised whether some patients at increased risk
of adverse outcomes with CABG might be better served
with PCI, even though CABG remained an option (28).
We proposed a clinical trial to compare the long-term
survival of patients with medically refractory unstable isch-
emia and a high risk of adverse outcome with CABG,
randomly allocated between a CABG strategy and a PCI
strategy (26,28). From the Veterans Affairs (VA) Continu-
ous Improvement in Cardiac Surgery Program database, we
identified five risk factors associated with increased 30-day
postoperative mortality. The risk factors were: 1) prior heart
surgery; 2) age .70 years; 3) LVEF ,0.35; 4) intraaortic
balloon pump (IABP) before surgery; and 5) MI ,7 days
before CABG (29,30). This paper presents the three-year
survival results of the randomized clinical trial.
METHODS
The Angina With Extremely Serious Operative Mortality
Evaluation (AWESOME) trial began enrollment in Feb-
ruary 1995 and completed enrollment on March 31, 2000.
Over the five-year period, 16 VA Medical Centers partici-
pated, with 11 sites enrolling throughout the entire period
and five sites enrolling for periods of two to three years.
Methodological issues have been presented in a design
manuscript published by the Society for Clinical Trials (28).
Patient screening and accrual. Patient screening took
place in a five-step process (28). The first three steps
consisted of identifying clinically eligible patients who had
medically refractory myocardial ischemia and one or more of
the five risk factors. Myocardial ischemia was defined as one
or more of the following: 1) rest angina with reversible
electrocardiographic changes; 2) rest angina in a patient
with prior MI or angiographically confirmed CAD; 3)
recurrent rest angina; 4) rest angina within seven days of an
acute MI; or 5) unstable angina that had been stabilized
medically, with a subsequent positive provocative test for
ischemia. Medically refractory ischemia was defined as
ischemia that persisted despite a regimen that included
aspirin or intravenous heparin and at least one of the
following: heart rate ,60 beats/min and systolic blood
pressure ,120 mm Hg, enough antianginal drug so that
resting heart rate remains at ,70 beats/min or systolic blood
pressure ,150 mm Hg or IABP required to stabilize or
significant contraindication to both beta-adrenergic block-
ing agents and calcium channel blocking agents (25,26).
The definition of medically refractory ischemia had to be
broad enough to safely include very elderly patients, patients
with severe degrees of ventricular dysfunction and patients
with advanced degrees of pulmonary, renal or hepatic comor-
bidity (25,26). To be considered a high risk, the patient had
to have one or more of the five risk factors associated with
increased 30-day operative mortality (29,30).
Specific exclusions from the randomized trial included
any of the following: single-vessel circumflex disease, un-
protected (ungrafted) .50% left main stenosis, no graftable
or dilatable vessels or comorbidity likely to limit the pa-
tient’s life to a greater extent than his (her) coronary disease
or angioplasty within six months.
Patients who met the three clinical eligibility criteria
(myocardial ischemia, medically refractory, high-risk of
adverse outcomes with CABG) underwent coronary an-
giography, which was reviewed by both a surgeon and an
interventional cardiologist. Clinically eligible patients who
had coronary anatomy deemed acceptable for random as-
signment between revascularization strategies were ap-
proached for informed consent to participate in the trial.
A total of 22,662 patients were screened, and 20,231 were
excluded because they did not meet all three clinical
requirements. Among the screened patients, 7,278 did not
meet the myocardial ischemia criteria; 5,783 did not meet
the medically refractory criteria, and 10,030 did not have at
least one of the high-risk factors. The sum of these three
exclusion groups is greater than the 22,662 screened because
of overlap between exclusion groups. A total of 2,431
patients met all three criteria and was clinically eligible.
After coronary angiography had been reviewed by both
interventional cardiologist and surgeon, a total of 781 (32%)
was angiographically acceptable to both operators as candi-
dates for random allocation of revascularization method. These
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patients were approached for informed consent, and 454 (58%)
consented to a randomized choice of revascularization.
Study details. Randomization was under the direction of
the study biostatistician at the Hines VA Cooperative Studies
Program Coordinating Center. Patients were stratified by
hospital, age (,70, .70 years) and prior heart surgery (yes,
no). The co-chairmen and local site investigators were blinded
from the study results throughout the course of the study.
The primary outcome of the trial was survival. Death
records were completed on each patient who died during the
course of the trial by the research nurse coordinators.
Patient records were also matched with VA death records
recorded in the VA Beneficiary Identification and Record
Locator Subsystem database to check survival information.
Unstable angina, repeat hospitalization, repeat catheteriza-
tion, repeat CABG and repeat PCI were obtained from the
follow-up visits and rechecked against the Patient Treat-
ment File, an independent hospital discharge database
maintained by the Department of the VA. As an outcome,
unstable angina was defined as angina that is either new
onset, progressive or occurring at rest (25–28).
Statistical methods. The baseline comparability of the
cohorts randomized to PCI and CABG is assessed by
chi-square tests for proportions and Student t tests for
continuous data. Kaplan-Meier survival estimates were used
to estimate the primary end point, and the survival estimates
were used to generate survival plots. The log-rank test
provided a global statistical significance test for the CABG
and PCI survival plots. The secondary end points of
combined survival and freedom from unstable angina and
combined survival and freedom from unstable angina and
repeat revascularization were evaluated by comparing
Kaplan-Meier plots and log-rank tests. All analyses are based
on cohorts specified by the intention-to-treat principle.
Sample size and power calculations were discussed in the
methods manuscript (28). All sample size calculations were
two-sided. The final sample size has a power of 80% to
detect a 9% survival difference at 36 months between
CABG and PCI (82% vs. 73%) based on a two-sided test
with a type I error of 5%.
RESULTS
Baseline comparability of CABG and PCI cohorts. Ta-
ble 1 presents selected baseline clinical and angiographic
variables for the CABG and PCI groups. Coronary artery
bypass graft surgery and PCI profiles are similar for all baseline
variables except for angiographic thrombus. This single statis-
tically significant difference among all the baseline comparisons
is well within what would be expected by sampling variation.
CABG and PCI methods. The numbers of distal anasta-
moses performed were relatively stable at 2.9 across the five
years of the study. The use of arterial conduits increased
somewhat with average use over the five years. Left internal
mammary use increased from 57% in 1995 to 78% in
1999/2000 with an overall rate of 70%. Right internal
mammary use increased from 1.4% in 1995 to 4.8% in
1999/2000 with an overall rate of 3.4%, and radial artery use
increased from 1.4% in 1995 to 4.0% in 1999/2000 with an
overall rate of 2.8%.
Table 2. Short-Term Outcomes of Patients Randomly Assigned
to CABG or PCI
Outcomes
CABG
n (%)
PCI
n (%)
PCI-CABG
Difference
(SE)
% (%)
Randomized 232 (100%) 222 (100%)
Revascularized 227 (98%) 221 (99.5%) 1.5% (1.5%)
Received CABG 217 (94%) 8 (3.5%)
Received PCI 12 (5%) 220 (99%)
Received only CABG 215 (93%) 1 (0.5%)
Received only PCI 10 (4%) 213 (96%)
Received CABG and PCI 2 (1%) 7 (3%) 2% (1.8%)
Stroke 3 (1%) 2 (1%) 0% (1.3%)
Survival
30 days (95%) (97%) 2% (2.6%)
6 months (90%) (94%) 4% (2.4%)
CABG 5 coronary artery bypass graft surgery; PCI 5 percutaneous coronary
intervention; SE 5 standard error.
Table 1. Baseline Comparison of Clinical Variables of Patients
Randomly Assigned to CABG or PCI
Baseline CABG PCI
Number of patients 232 222
Age (yr) 67 67
Medical therapy
ASA 88% 88%
Heparin 64% 61%
Beta-blocker 76% 76%
Calcium blocker 36% 27%
High risk factors
Age . 70 53% 50%
Prior CABG 32% 30%
Myocardial infarction , 7 days 32% 35%
LVEF , 0.35 23% 18%
IABP required 2% 2%
Two or more high risk factors 35% 32%
Risk factors
Hypertension 69% 67%
Diabetes 34% 29%
Prior PCI 22% 17%
Prior myocardial infarction 71% 70%
Prior stroke 14% 9%
LVEF 0.44 0.47
Native coronary disease
One-vessel CAD 17% 20%
Two-vessel CAD 33% 40%
Three-vessel CAD 50% 40%
Left anterior descending .70% 88% 87%
Thrombus containing lesions 11% 21%
Highest ACC/AHA class
A 5% 4%
B 36% 38%
C 59% 59%
ACC/AHA 5 American College of Cardiology/American Heart Association;
ASA 5 aspirin; CABG 5 coronary artery bypass grafting; CAD 5 coronary artery
disease; IABP 5 intra-aortic balloon pump; LVEF 5 left ventricular ejection
fraction; PCI 5 percutaneous coronary intervention.
145JACC Vol. 38, No. 1, 2001 Morrison et al.
July 2001:143–9 PCI Versus CABG in High-Risk Myocardial Ischemia
Use of stents increased from 26% of cases in 1995 to 88%
of cases in 1999/2000 with an overall rate of 54%. Similarly,
use of glycoprotein IIb/IIIa receptor blocking agents as
adjuncts to PCI increased from 1% in 1995 to 52% in
1999/2000 with an overall rate for the study of 11%. The
use of intraaortic balloon counter-pulsation decreased from
21% of PCI cases in 1995 to 10% in 1999/2000. There was
no use of cardiopulmonary support or heart-lung bypass as
an adjunct for PCI throughout the course of the study. By
1998 there was no further use of directional atherectomy.
Short-term outcomes. Table 2 compares the CABG and
PCI short-term outcomes. Of the 232 patients randomized
to receive CABG, 227 (98%) were revascularized; 215
(93%) received only CABG; 12 (5%) received PCI (two in
addition to CABG), and 5 (2%) were not revascularized.
The in-hospital mortality of the CABG cohort was 4% (n 5
8), and the 30-day mortality was 5%. Stroke, renal failure
requiring dialysis and mediastinitis were each seen in three
patients (1%). Of the 222 patients randomized to PCI, 221
(99.5%) were revascularized; 213 (96%) received only PCI;
8 (3.5%) received CABG (seven after PCI), and one patient
(0.5%) died before a scheduled PCI. In-hospital mortality in
the PCI cohort was 1% (n 5 2), and the 30-day mortality
was 3%. Stroke was 1% (n 5 2), and renal failure requiring
dialysis was 2% (n 5 4) in the PCI cohort. Within 30 days
of revascularization, none of the CABG patients underwent
repeat CABG, but four patients (2%) underwent PCI. Within
30 days of revascularization, five (2%) of the PCI patients
underwent repeat PCI, and nine (4%) underwent CABG.
Long-term outcomes. Table 3 compares the 36-month
survival, survival free of unstable angina and survival free of
unstable angina and repeat revascularization for the cohorts
randomly allocated between CABG and PCI.
Figure 1 presents the five-year Kaplan-Meier survival
curves for the CABG and PCI cohorts. The log-rank test
for global differences between the two survival curves is not
statistically significant (p 5 0.46). The CABG and PCI
number of patients (N) and the percentage surviving for
each time period are shown.
Figure 2 presents the five-year Kaplan-Meier survival
curves for the combined end point of survival free of unstable
angina. Coronary artery bypass graft surgery survival free of
unstable angina is generally greater than the corresponding
PCI survival rate, but the PCI rate is approximately 90% of the
CABG rate. The log-rank test for global differences between
the two curves is not statistically significant (p 5 0.16).
The CABG and PCI number (N) of patients and the
percentage surviving free of unstable angina for each time
period are shown.
Figure 3 presents the five-year Kaplan-Meier curves for
the combined end points of survival free of unstable angina
Table 3. Coronary Artery Bypass Graft Surgery and PCI 36-
Month Survival, Survival Free of Unstable Angina and Survival
Free of Unstable Angina or Repeat Revascularizations
Outcome CABG PCI
PCI-CABG
(Difference)
SE
(Difference)
Survival 79% 80% 1% 3.7%
Survival free of unstable
angina
65% 59% 24% 5.5%
Survival free of unstable angina
or repeat revascularization
61% 48% 213% 5.0%
CABG 5 coronary artery bypass graft surgery; PCI 5 percutaneous coronary
intervention; SE 5 standard error.
Figure 1. Kaplan-Meier survival plot of coronary artery bypass graft surgery (CABG) (circles) versus percutaneous coronary intervention (PCI) (squares).
The CABG and PCI number of patients (N) and the percentage surviving for each time period are shown at the bottom of the plot.
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or repeat revascularization. Coronary artery bypass graft
surgery survival free of unstable angina and repeat revascu-
larizations is generally greater than the corresponding PCI
rates, and the log-rank test for global differences between
the two curves is statistically significant (p 5 0.001). The
CABG and PCI number (N) of patients and the percentage
surviving free of unstable angina or repeat revascularizations
for each time period are shown.
DISCUSSION
The AWESOME study was designed to compare long-
term survival between PCI and CABG in patients with
medically refractory ischemia and increased risk of adverse
outcomes with CABG (26,28). The primary result of this
trial is comparable survival of patients randomly allocated
between CABG and PCI. The additional finding that PCI
Figure 3. Kaplan-Meier plot of survival free of unstable angina (UA) or repeat revascularization for coronary artery bypass graft surgery (CABG) (circles)
versus percutaneous coronary intervention (PCI) (squares). The CABG and PCI number of patients (N) and the percentage surviving free of UA or repeat
revascularizations for each time period are shown at the bottom of the plot.
Figure 2. Kaplan-Meier plot of survival free of unstable angina for coronary artery bypass graft surgery (CABG) (circles) versus percutaneous coronary
intervention (PCI) (squares). The CABG and PCI number of patients (N) and the percentage surviving free of unstable angina for each time period are
shown at the bottom of the plot.
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survival free of unstable angina was within 90% of the
CABG survival free of unstable angina also supports the
concept that PCI is an alternative for these patients. The
finding of more frequent repeat revascularization with a PCI
strategy is consistent with all previous CABG versus PCI
comparisons and reflects the differences in restenosis and
completeness of revascularization, which are implicit in the
two methods (15–24).
AWESOME patient population compared with previous
revascularization trials. The contribution this trial makes
to the comparison of CABG and PCI derives primarily
from its focus on high-risk patients (31). This is the only
trial, to our knowledge, that compares CABG and PCI in
patients with myocardial ischemia recruited because they
were both medically refractory and had risk factors for
adverse outcomes with CABG (15–24,26,28,31). The mean
age of AWESOME randomized trial patients of 67 years is
at least five years older than the mean age of patients random-
ized in the Emory Angioplasty Surgery Trial (EAST) (62
years), Bypass Angioplasty Revascularization Investigation
(BARI) (61 years) and the other PCI versus CABG trials
(15–22). Similarly, the mean LVEF of AWESOME patients
(0.45) is .0.10 lower than the mean values for any previous
randomized trial comparing CABG with PCI (15–22).
Prior CABG (31% of AWESOME patients) has been an
exclusion criterion from all previous trials (15–22). Most
previous trials have excluded patients who had an MI within
seven days (33% of AWESOME patients) (15–22).
Medically refractory ischemia and processes of care. For
this trial we attempted to push categories of medicines
toward physiologic heart rate and blood pressure targets
(25,26). The problem with a “one-size-fits-all” definition is
that there is a different risk of lowering heart rate and blood
pressure in patients with normal LVEF, versus severely
reduced LVEF, and in patients who are .80 years as
opposed to ,60 years old (25). Nonetheless, to our knowl-
edge, this is the first revascularization trial to attempt to
limit enrollment to patients who had failed any predefined
medical regimen. Largely as a result of the attempt to define
medically refractory angina, a large proportion of AWE-
SOME patients were receiving aspirin, heparin, nitrates and
beta-blockers. Of the patients coming to diagnostic cathe-
terization before enrollment in the AWESOME random-
ized trial, 88% were receiving aspirin; 62% were receiving
heparin; 90% were receiving nitrates; 76% were receiving
beta-blockers, and 31% were receiving calcium channel
blockers. This is in contrast with aspirin use (45% and 49%),
heparin use (31% and 32%), beta-blocker use (50% and
34%) and calcium channel blocker use (76% and 76%) in
BARI and EAST, respectively (18,21,22). The data sup-
porting nearly routine use of statin lipid-lowering agents
and angiotensin-converting enzyme inhibition were not
available when AWESOME was being planned.
Comparison of revascularization processes of care. With
regard to surgical processes of care, 70% of AWESOME
surgical patients received left internal mammary grafts; 3.2%
received right internal mammary grafts, and 2.9% received
radial artery grafts. By contrast, BARI and EAST surgical
patients received internal mammary grafts in 84% and 86%
of cases, respectively (18,21).
With regard to percutaneous interventional processes of
care, 54% of AWESOME patients undergoing PCI re-
ceived stents with an increase from 26% in 1995 to 88% in
1999/2000. Overall, 11% of AWESOME patients undergoing
PCI received glycoprotein IIb/IIIa receptor blocking agents
with an increase from 1% in 1995 to 51% in 1999/2000.
Neither stents nor glycoprotein IIb/IIIa receptor blocking
agents were used in either BARI or EAST (18,21).
Study limitations. The most important limitation of this
trial is not having a larger sample size from which to derive
greater statistical power. Most of this limitation appears to
derive from the large proportion of clinically eligible pa-
tients for whom the physicians felt one of the two revascu-
larization choices was preferable and, therefore, would not
permit random allocation. Physician clinical judgment fa-
vored nonrandom allocation for 1,650 patients (68% of the
clinically eligible patients). The lack of a core laboratory for
central adjudication of electrocardiograms was the major
reason for not including myocardial infarction as a second-
ary outcome measure. The lack of a core laboratory for
adjudication of coronary angiograms was the major reason
for not investigating relative patency rates. The unavailabil-
ity of large numbers of female patients is a recognized
limitation of VA trials.
Conclusions. Percutaneous coronary intervention is an al-
ternative to CABG for some patients with medically refrac-
tory myocardial ischemia and a high risk of adverse out-
comes with CABG. Patients with medically refractory
myocardial ischemia and one or more of these risk factors
have a comparable three-year survival but a higher rate of
repeat revascularization with initial PCI.
APPENDIX
Participants in Veterans Affairs Cooperative Study #385:
AWESOME
Executive Committee: Douglass Morrison, MD; Stewart
Scott, MD (deceased); Gulshan Sethi, MD; Jerome Sacks,
PhD; William Henderson, PhD; Steven Sedlis, MD; Rick
Esposito, MD; Dan Lewis, MD; Edward Folland, MD;
David Talley, MD.
Data Monitoring Board: Spencer King, III, MD (chair-
man); Cindy Grines, MD; Sidney Levitsky, MD; Bruce
Lytle, MD; Daniel Seigel, ScD
Death Review Committee: David Holmes, MD; Hartzell
V. Schaff, MD.
Department of Veterans Affairs Headquarters Staff: John R.
Feussner, MD, Chief Research and Development Officer;
Steven Berkowitz, PhD, Assistant Director, Cooperative
Studies Program; Joseph Gough, MA, Program Assistant,
Cooperative Studies Program.
Participating Sites: Albuquerque, New Mexico; Ann Ar-
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bor, Michigan; Asheville, North Carolina; Dallas, Texas;
Denver, Colorado; Durham, North Carolina; Lexington,
Kentucky; Little Rock, Arkansas; Memphis, Tennessee;
Minneapolis, Minnesota; New York, New York; Portland,
Oregon; San Antonio, Texas; Tucson, Arizona; West Los
Angeles, California; West Roxbury, Massachusetts.
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